Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
The health ministry’s Central Social Insurance Medical Council, better known as Chuikyo, on December 14 approved Japan Tobacco’s anti-HIV drug Descovy (emtricitabine + tenofovir alafenamide fumarate) for NHI reimbursement price listing on December 21. The drug’s low-dose and high-dose versions,…
To read the full story
Related Article
- HIV Med Descovy Approved in Japan
December 12, 2016
- Japan NDA Filed for Gilead’s HIV Drug Descovy
August 16, 2016
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





